• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Introduction to FluoGuide

FLUO28.02.2024, 10.45
HC Andersen Capital

Join us for a virtual live event on February 28 at 10.45, for an in-depth introduction to FluoGuide, a pioneer in precision cancer surgery. FluoGuide’s CEO, Morten Albrechtsen will here elaborate on the company’s innovative technology and exciting pipeline.

FluoGuide lights up cancer for greater surgical precision, improving the outcome for cancer patients through fluorescence-guided surgery. Their lead compound, FG001, has already shown promising results in Phase II trials for use in aggressive brain, head & neck, and lung cancers.

At this virtual event, you will also have the opportunity to ask questions directly to FluoGuide’s CEO.

Disclaimer: HC Andersen Capital receives payment from FluoGuide for a DigitalIR/Corporate Visibility agreement./Claus Thestrup kl. 16.50, 20-02-2024.

Upcoming webcasts

Recent videos

HCA Morgenbørs 04/08 - Positiv åbning på forventninger om en nedtrapning af konflikten i Iran
04.08.2026, 09.16 Novo Nordisk
Asmodee, Audiocast, Q1'26
04.08.2026, 09.00 Asmodee
Aspo Oyj, Webcast, Q2'26
03.08.2026, 11.00 Aspo
HCA Morgenbørs 03/08 - Prisfald i olie driver positivt marked
03.08.2026, 09.28 Novo Nordisk
Outokumpu, Webcast, Q2'26
30.07.2026, 13.30 Outokumpu
View all videos